IGF-1 LR3 Infusion Acutely Reduces Fetal Sheep Insulin Secretion, Effect Not Intrinsic to Islets
Background
Insulin-like Growth Factor-1 (IGF-1) is a critical hormone for fetal growth and development, but its dysregulation can significantly impact glucose homeostasis and insulin sensitivity. While IGF-1 is known to influence metabolic processes, the precise mechanisms by which it affects glucose-stimulated insulin secretion (GSIS) in the developing fetus, specifically whether its actions are direct on pancreatic beta cells or mediated by systemic factors, remain unclear. This study investigated the acute effects of IGF-1 LR3 on GSIS in fetal sheep and determined if these effects are intrinsic to the pancreatic islets.
Study Design
Results
In the in vivo fetal sheep model, acute IGF-1 LR3 infusion significantly attenuated glucose-stimulated insulin secretion (GSIS). Specifically, during glucose infusion, plasma insulin concentrations were observed to be 25% lower in the IGF-1 LR3-treated group compared to the control group (p<0.05), indicating a substantial reduction in insulin release. However, when islets were isolated from these same IGF-1 LR3-treated fetuses and tested in vitro, their capacity for glucose-stimulated insulin secretion was found to be normal, showing no significant difference compared to islets from control animals (p>0.05). This suggests that the acute suppressive effect of IGF-1 LR3 on insulin secretion observed in the intact fetal sheep is likely mediated by systemic factors rather than a direct, persistent impairment of the pancreatic beta cells themselves. This indicates that the acute suppressive effect of IGF-1 LR3 on insulin secretion observed in the intact fetal sheep is likely mediated by systemic factors rather than a direct, persistent impairment of the pancreatic beta cells themselves. This implies a transient, indirect mechanism rather than a lasting cellular defect within the islets.
Why It Matters
This research highlights a complex interplay between IGF-1 and fetal glucose metabolism, suggesting that the in vivo effects of IGF-1 LR3 on insulin secretion are not solely due to direct actions on pancreatic beta cells. Understanding these indirect, systemic mechanisms is crucial for comprehending how fetal growth factors influence metabolic programming and the long-term risk of metabolic diseases in offspring. This finding could inform strategies for managing conditions like fetal growth restriction or macrosomia, potentially leading to novel therapeutic approaches that target systemic mediators rather than the islets directly. Further research is needed to identify the specific systemic factors involved and to translate these findings into human clinical trials.